This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

Tipranks - Tipranks - Thu Aug 6, 4:22AM CDT

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences, with a price target of $165.00. The company’s shares closed yesterday at $135.25.

Claim 55% Off TipRanks

According to TipRanks, Bansal is a 5-star analyst with an average return of 10.4% and a 58.91% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Vertex Pharmaceuticals.

In addition to Wells Fargo, Gilead Sciences also received a Buy from Needham’s Joseph Stringer in a report issued today. However, on August 3, Goldman Sachs maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

See today’s best-performing stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.96 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $6.67 billion and had a net profit of $1.32 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).